Isomorphic Labs' high valuation signals AI's growing role in drug development

STAT News examines Isomorphic Labs' valuation as a bellwether for AI in drug discovery, highlighting investor confidence despite unresolved questions about AI's impact on healthcare costs. The piece underscores the ongoing debate over whether AI-driven efficiencies will reduce or inflate overall care expenses.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works